NAV

Bizalimogene ralaplasmid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bizalimogene ralaplasmid
DrugBank Accession Number
DB16113
Background

Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2).

Type
Biotech
Groups
Investigational
Synonyms
  • Bizalimogene ralaplasmid
External IDs
  • pGX-3002
  • pGX3002
  • VGX-3100

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
D8W2DVO5ZJ
CAS number
1977488-08-6

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCervical Dysplasia / Cervical High Grade Squamous Intraepithelial Lesion (HSIL) / HSIL2
2Active Not RecruitingTreatmentHuman Papillomavirus-16 Positive / Human Papillomavirus-18 Positive / Metastatic Cancer / Recurrent Anal Canal Carcinoma / Recurrent Cervical Carcinoma / Recurrent Malignant Neoplasm / Recurrent Penile Carcinoma / Recurrent Vaginal Carcinoma / Recurrent Vulvar Carcinoma / Refractory Malignant Neoplasm / Stage IV Anal Cancer AJCC v8 / Stage IV Cervical Cancer AJCC v8 / Stage IV Penile Cancer AJCC v8 / Stage IV Vaginal Cancer AJCC v8 / Stage IV Vulvar Cancer AJCC v8 / Stage IVA Cervical Cancer AJCC v8 / Stage IVA Vaginal Cancer AJCC v8 / Stage IVA Vulvar Cancer AJCC v8 / Stage IVB Cervical Cancer AJCC v8 / Stage IVB Vaginal Cancer AJCC v8 / Stage IVB Vulvar Cancer AJCC v81
2CompletedTreatmentAnal Neoplasms1
2CompletedTreatmentCervical Intraepithelial Neoplasia (CIN)1
2CompletedTreatmentHuman Papilloma Virus (HPV) / Precancerous Lesions of the Vulva / VIN 2 / VIN 3 / Vulvar Dysplasia / Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) / Vulvar Intraepithelial Neoplasia (VIN)1
2RecruitingTreatmentAnal Intraepithelial Neoplasia (AIN) / High Grade Squamous Intraepithelial Neoplasia / HIV Positivity / Human Papillomavirus-16 Positive / Human Papillomavirus-18 Positive1
1CompletedTreatmentHuman Papilloma Virus (HPV)1
1CompletedTreatmentPapilloma Viral Infection1
1, 2CompletedTreatmentCervical Cancer1
1, 2CompletedTreatmentSquamous Cell Cancers of the Head and Neck1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 18:12 / Updated at February 21, 2021 18:55